Strongbridge Biopharma PLC (NASDAQ:SBBP) posted its quarterly earnings results on Monday. The biotechnology company reported ($0.34) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.34), MarketWatch Earnings reports.

Shares of Strongbridge Biopharma PLC (SBBP) traded down 2.82% during mid-day trading on Monday, reaching $6.90. 15,211 shares of the company’s stock traded hands. The company’s market capitalization is $243.81 million. The firm has a 50-day moving average price of $6.33 and a 200-day moving average price of $4.42. Strongbridge Biopharma PLC has a 1-year low of $2.00 and a 1-year high of $8.85.

A number of large investors have recently bought and sold shares of the company. State of Wisconsin Investment Board bought a new stake in Strongbridge Biopharma PLC during the second quarter valued at $114,000. Rhumbline Advisers bought a new stake in Strongbridge Biopharma PLC during the second quarter valued at $154,000. Bank of New York Mellon Corp bought a new stake in Strongbridge Biopharma PLC during the second quarter valued at $331,000. Schwab Charles Investment Management Inc. bought a new stake in Strongbridge Biopharma PLC during the second quarter valued at $332,000. Finally, Broadfin Capital LLC raised its stake in Strongbridge Biopharma PLC by 3.0% in the first quarter. Broadfin Capital LLC now owns 2,981,706 shares of the biotechnology company’s stock valued at $14,163,000 after buying an additional 87,125 shares during the period.

Several research firms recently commented on SBBP. Zacks Investment Research upgraded shares of Strongbridge Biopharma PLC from a “hold” rating to a “buy” rating and set a $7.75 price target on the stock in a report on Wednesday, July 19th. ValuEngine upgraded shares of Strongbridge Biopharma PLC from a “sell” rating to a “hold” rating in a report on Tuesday, June 27th. Finally, HC Wainwright restated a “buy” rating on shares of Strongbridge Biopharma PLC in a report on Wednesday, May 17th.

TRADEMARK VIOLATION WARNING: “Strongbridge Biopharma PLC (NASDAQ:SBBP) Announces Quarterly Earnings Results, Hits Estimates” was first published by American Banking News and is the property of of American Banking News. If you are accessing this article on another domain, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The correct version of this article can be read at https://www.americanbankingnews.com/2017/08/07/strongbridge-biopharma-plc-nasdaqsbbp-announces-quarterly-earnings-results-hits-estimates.html.

Strongbridge Biopharma PLC Company Profile

Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for a range of diseases. The Company’s commercial product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic and related variants of primary periodic paralysis.

Receive News & Ratings for Strongbridge Biopharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strongbridge Biopharma PLC and related companies with MarketBeat.com's FREE daily email newsletter.